- Home
- WPM vs TAK Comparison
WPM vs TAK Comparison
Compare WPM & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPM
- TAK
- Stock Information
- Founded
- WPM 2004
- TAK 1781
- Country
- WPM Canada
- TAK Japan
- Employees
- WPM N/A
- TAK N/A
- Industry
- WPM Precious Metals
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- WPM Basic Materials
- TAK Health Care
- Exchange
- WPM Nasdaq
- TAK Nasdaq
- Market Cap
- WPM 40.9B
- TAK 45.8B
- IPO Year
- WPM 2004
- TAK N/A
- Fundamental
- Price
- WPM $91.04
- TAK $14.68
- Analyst Decision
- WPM Strong Buy
- TAK
- Analyst Count
- WPM 8
- TAK 0
- Target Price
- WPM $87.88
- TAK N/A
- AVG Volume (30 Days)
- WPM 1.7M
- TAK 2.2M
- Earning Date
- WPM 08-07-2025
- TAK 07-30-2025
- Dividend Yield
- WPM 0.70%
- TAK 3.70%
- EPS Growth
- WPM 4.62
- TAK N/A
- EPS
- WPM 1.36
- TAK 0.45
- Revenue
- WPM $1,458,244,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- WPM $38.25
- TAK $1.01
- Revenue Next Year
- WPM $2.93
- TAK $1.04
- P/E Ratio
- WPM $66.82
- TAK $65.09
- Revenue Growth
- WPM 32.76
- TAK 7.45
- 52 Week Low
- WPM $53.05
- TAK $12.80
- 52 Week High
- WPM $95.23
- TAK $15.53
- Technical
- Relative Strength Index (RSI)
- WPM 54.98
- TAK 41.31
- Support Level
- WPM $85.59
- TAK $14.93
- Resistance Level
- WPM $92.76
- TAK $15.14
- Average True Range (ATR)
- WPM 2.65
- TAK 0.15
- MACD
- WPM -0.21
- TAK -0.06
- Stochastic Oscillator
- WPM 76.01
- TAK 11.86
About WPM Wheaton Precious Metals Corp (Canada)
Wheaton Precious Metals Corp is a precious metal streaming company. The company metal streaming company which generates its revenue primarily from the sale of precious metals (gold, silver and palladium) and cobalt. Its reportable segment includes: Gold, Silver, Palladium, Platinum, Cobalt, and Other.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.